Full U.S. Prescribing Information
TOPAMAX Product Information
The following information provided by Janssen Pharmaceuticals, Inc. does not take the place of a discussion with your doctor, pharmacist, or other healthcare professional about the risks and benefits of TOPAMAX. It is important to speak with one of these healthcare professionals about any prescribed medication.
You will need Adobe Acrobat Reader to view and print this publication. If you don't have it already, click here to download.
Access2wellness™ provides access to more than 1,000 free and discounted prescription medications for uninsured and underinsured individuals who qualify.
TOPAMAX® is approved as initial monotherapy in patients 2 years of age and older with partial-onset or primary generalized tonic-clonic seizures.
Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.
TOPAMAX® is approved as add-on therapy for patients 2 years of age and older with primary generalized tonic-clonic seizures, partial-onset seizures, or seizures associated with Lennox-Gastaut syndrome.